Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-10-06
1996-12-10
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514475, A61K 31335
Patent
active
055831532
ABSTRACT:
An improved method of suppression of a progressive, inflammatory, autoimmune arthritis in a mammal involves the use of the drug Taxol. In general, such a method comprises administering to a mammal having or susceptible to arthritis Taxol in a pharmacologically acceptable carrier capable of solubilizing Taxol in a dose sufficient to suppress at least one symptom of arthritis selected from the group of inflammation, swelling, abnormal neovascularization, bone erosion, and cartilage erosion. The use of Taxol can be combined with the use of other antiarthritic drugs, such as the angiogenesis inhibitor AGM-1470, to produce a greater therapeutic effect than with either Taxol or the other antiarthritic drug alone.
REFERENCES:
Brahn et al; "Regression of Collagen-Induced Arthritis with Taxol, a Microlubule Stabilizer", Arthritis and Rheumatism; vol. 37, 14.0.6, Jun. 1994, pp. 839-845.
S. J. Oliver et al., "Suppression of Collagen-Induced Arthritis Using an Angiogenesis Inhibitor, AGM-1470, and a Microtubule Stabilizer, Taxol," Cell. Immunol. 157:291-299 (1994).
E. K. Rowinsky, "Taxol: A Novel Investigational Antimicrotubule Agent," J. Nat. Cancer Inst. 82: 1247-1259 (1990).
C. M. Spencer & D. Faulds, "Paclitaxel: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Treatment of Cancer," Drugs 48:794-847 (1994).
D. Bissett & S. B. Kaye, "Taxol and Taxotere--Current Status and Future Prospects," Eur. J. Cancer 29A: 1228-1231 (1993).
J. G. Kuhn, "Pharmacology and Pharmacokinetics of Paclitaxel," Ann. Pharmacother. 28: S15-S18 (1994).
D. S. Sonnichsen & M. V. Relling, "Clinical Pharmacokinetics of Paclitaxel," Clin. Pharmacokinet. 27: 256-269 (1994).
D. R. Kohler & B. R. Goldspeil, "Evaluation of New Drugs: Paclitaxel (Taxol)," Pharmacotherapy 14: 3-34 (1994).
J. L. Eiseman et al., "Plasma Pharmacokinetics and Tissue Distribution of Paclitaxel in CD.sub.2 F.sub.1 Mice," Cancer Chemother. Pharmacol. 34: 465-471 (1994).
E. D. Harris, Jr., "Rheumatoid Arthritis: Pathophysiology and Implications for Therapy," New Eng. J. Med. 322: 1277-1289 (1990).
D. Ingber et al., "Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumor Growth," Nature 348: 555-557 (1990).
(Abstract) C. Tang et al., "Regression of Collagen-Induced Arthritis with Taxol, a Microtubule Stabilizer," Arth. Rheum. 36 (Supplement): S45 (1993) .
Criares Theodore J.
Regents of the University of California
LandOfFree
Use of taxol in the treatment of rheumatoid arthritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of taxol in the treatment of rheumatoid arthritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of taxol in the treatment of rheumatoid arthritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-424528